Home › Companies › BIOMARIN PHARMACEUTICAL INC. › 2024-2025
Download data (CSV): ballot items · votes by manager · column guide.
Compiled from SEC Form N-PX filings and BIOMARIN PHARMACEUTICAL INC.’s Form 8-K, filed May 22, 2025 (Item 5.07 on EDGAR). Page generated November 20, 2026.
Meeting of May 20, 2025: 13 items on BIOMARIN PHARMACEUTICAL INC.’s Form 8-K, filed May 22, 2025: 10 elected · 3 approved.
No notable dissent.
Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided
Explore BIOMARIN PHARMACEUTICAL INC. in the interactive database Compare manager voting policies
These tallies are BIOMARIN PHARMACEUTICAL INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed May 22, 2025 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| Elect Director: Elizabeth M. Anderson | 160,575,395 | 5,338,859 | 261,996 | -- | 10,064,270 | 97% | Elected | — |
| Elect Director: Barbara W. Bodem | 164,230,278 | 1,033,669 | 912,303 | -- | 10,064,270 | 99.4% | Elected | — |
| Elect Director: Athena Countouriotis | 163,915,734 | 1,656,229 | 604,287 | -- | 10,064,270 | 99% | Elected | — |
| Elect Director: Willard Dere | 163,380,097 | 2,536,182 | 259,971 | -- | 10,064,270 | 98% | Elected | — |
| Elect Director: Mark J. Enyedy | 164,211,417 | 1,412,156 | 552,677 | -- | 10,064,270 | 99.1% | Elected | — |
| Elect Director: Alexander Hardy | 164,875,088 | 1,051,826 | 249,336 | -- | 10,064,270 | 99.4% | Elected | — |
| Elect Director: Maykin Ho | 164,039,826 | 1,878,694 | 257,730 | -- | 10,064,270 | 99% | Elected | — |
| Elect Director: Robert J. Hombach | 163,224,408 | 2,694,927 | 256,915 | -- | 10,064,270 | 98% | Elected | — |
| Elect Director: Richard A. Meier | 160,566,321 | 5,338,585 | 271,344 | -- | 10,064,270 | 97% | Elected | — |
| Elect Director: Timothy P. Walbert | 165,166,799 | 662,209 | 347,242 | -- | 10,064,270 | 99.6% | Elected | — |
| 2. Ratification of the Selection of Independent Registered Public Accounting Firm The ratification of the selection of KPMG LLP as BioMarin's independent registered public accounting firm for the fiscal year ending December 31, 2025, as set forth in the Proxy | 168,601,089 | 7,442,009 | 197,422 | -- | -- | 96% | Approved | — |
| 3. Advisory Vote on the Compensation of Named Executive Officers The advisory (non-binding) vote to approve the compensation of BioMarin's named executive officers, as set forth in the Proxy Statement | 155,351,652 | 10,227,321 | 597,277 | -- | 10,064,270 | 94% | Approved | — |
| 4. Approval of an Amendment to the 2017 Equity Incentive Plan The approval of the Plan Amendment | 157,280,864 | 7,747,768 | 1,147,618 | -- | 10,064,270 | 95% | Approved | — |
Source: BIOMARIN PHARMACEUTICAL INC., Form 8-K, filed with the SEC on May 22, 2025 — read the filing on EDGAR.
See voting trends for Health Care companies, 2024-2025: shareholder support by sector and by company size.
554 asset managers disclosed a vote on at least one BIOMARIN PHARMACEUTICAL INC. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report.
Combines 4 wordings of this item as funds reported it.
99.4% Majority: yes · of votes cast
Description as filed by funds: Election of Directors: Alexander Hardy
BIOMARIN PHARMACEUTICAL INC.’s own tally for this item (“Elect Director: Alexander Hardy”): 164,875,088 for, 1,051,826 against, per its Form 8-K filed May 22, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “Proposal 1: Election of Directors Based on the votes set forth above, BioMarin's stockholders elected each of the ten nominees set forth above to serve as a director of BioMarin until the next annual meeting of stockholders and until his or her successor is duly elected and qualified, or, if sooner…”
Support: 99.4% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 132 asset managers below reported 89,032,908 for, 6,597 against, 66,717 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 32,152,237 | 0 | 0 | 0 | For |
| BlackRock | 12,596,604 | 0 | 0 | 0 | For |
| Dodge & Cox | 11,525,325 | 0 | 0 | 0 | For |
| Capital Group | 8,669,069 | 0 | 0 | 0 | For |
| Fidelity | 3,339,881 | 0 | 0 | 0 | For |
| State Street | 3,100,000 | 0 | 0 | 0 | For |
| PRIMECAP Odyssey Funds | 2,994,376 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 2,813,621 | 0 | 0 | 0 | For |
| Charles Schwab | 1,505,451 | 0 | 0 | 0 | For |
| TIAA | 843,433 | 0 | 0 | 0 | For |
| Aberdeen | 721,531 | 0 | 0 | 0 | For |
| First Trust | 664,902 | 0 | 0 | 0 | For |
| Capitol Series Trust | 547,000 | 0 | 0 | 0 | For |
| TOUCHSTONE STRATEGIC TRUST | 517,507 | 0 | 0 | 0 | For |
| Dimensional | 488,764 | 0 | 0 | 0 | For |
| JPMorgan | 464,998 | 0 | 0 | 0 | For |
| American Century | 447,463 | 0 | 0 | 0 | For |
| Equitable | 381,070 | 0 | 0 | 0 | For |
| Jackson National | 359,423 | 0 | 0 | 0 | For |
| NEW ECONOMY FUND | 289,881 | 0 | 0 | 0 | For |
| Empower | 246,899 | 0 | 0 | 0 | For |
| AQR | 236,403 | 0 | 0 | 0 | For |
| Goldman Sachs | 218,905 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 213,459 | 0 | 0 | 0 | For |
| John Hancock | 191,443 | 0 | 0 | 0 | For |
Showing the 25 largest of 132 asset managers. All 132 are in the interactive database (link above).
Combines 4 wordings of this item as funds reported it.
99% Majority: yes · of votes cast
Description as filed by funds: Election of Directors: Athena Countouriotis
BIOMARIN PHARMACEUTICAL INC.’s own tally for this item (“Elect Director: Athena Countouriotis”): 163,915,734 for, 1,656,229 against, per its Form 8-K filed May 22, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “Proposal 1: Election of Directors Based on the votes set forth above, BioMarin's stockholders elected each of the ten nominees set forth above to serve as a director of BioMarin until the next annual meeting of stockholders and until his or her successor is duly elected and qualified, or, if sooner…”
Support: 99% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 132 asset managers below reported 88,999,138 for, 40,367 against, 66,717 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 32,152,237 | 0 | 0 | 0 | For |
| BlackRock | 12,596,604 | 0 | 0 | 0 | For |
| Dodge & Cox | 11,525,325 | 0 | 0 | 0 | For |
| Capital Group | 8,669,069 | 0 | 0 | 0 | For |
| Fidelity | 3,339,881 | 0 | 0 | 0 | For |
| State Street | 3,100,000 | 0 | 0 | 0 | For |
| PRIMECAP Odyssey Funds | 2,994,376 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 2,813,621 | 0 | 0 | 0 | For |
| Charles Schwab | 1,505,451 | 0 | 0 | 0 | For |
| TIAA | 843,433 | 0 | 0 | 0 | For |
| Aberdeen | 721,531 | 0 | 0 | 0 | For |
| First Trust | 664,902 | 0 | 0 | 0 | For |
| Capitol Series Trust | 547,000 | 0 | 0 | 0 | For |
| TOUCHSTONE STRATEGIC TRUST | 517,507 | 0 | 0 | 0 | For |
| Dimensional | 488,764 | 0 | 0 | 0 | For |
| JPMorgan | 464,998 | 0 | 0 | 0 | For |
| American Century | 447,463 | 0 | 0 | 0 | For |
| Equitable | 381,070 | 0 | 0 | 0 | For |
| Jackson National | 359,423 | 0 | 0 | 0 | For |
| NEW ECONOMY FUND | 289,881 | 0 | 0 | 0 | For |
| Empower | 246,899 | 0 | 0 | 0 | For |
| AQR | 236,403 | 0 | 0 | 0 | For |
| Goldman Sachs | 218,905 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 213,459 | 0 | 0 | 0 | For |
| John Hancock | 191,443 | 0 | 0 | 0 | For |
Showing the 25 largest of 132 asset managers. All 132 are in the interactive database (link above).
Combines 4 wordings of this item as funds reported it.
99.4% Majority: yes · of votes cast
Description as filed by funds: Election of Directors: Barbara W. Bodem
BIOMARIN PHARMACEUTICAL INC.’s own tally for this item (“Elect Director: Barbara W. Bodem”): 164,230,278 for, 1,033,669 against, per its Form 8-K filed May 22, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “Proposal 1: Election of Directors Based on the votes set forth above, BioMarin's stockholders elected each of the ten nominees set forth above to serve as a director of BioMarin until the next annual meeting of stockholders and until his or her successor is duly elected and qualified, or, if sooner…”
Support: 99.4% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 132 asset managers below reported 89,004,257 for, 35,248 against, 66,717 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 32,152,237 | 0 | 0 | 0 | For |
| BlackRock | 12,596,604 | 0 | 0 | 0 | For |
| Dodge & Cox | 11,525,325 | 0 | 0 | 0 | For |
| Capital Group | 8,669,069 | 0 | 0 | 0 | For |
| Fidelity | 3,339,881 | 0 | 0 | 0 | For |
| State Street | 3,100,000 | 0 | 0 | 0 | For |
| PRIMECAP Odyssey Funds | 2,994,376 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 2,813,621 | 0 | 0 | 0 | For |
| Charles Schwab | 1,505,451 | 0 | 0 | 0 | For |
| TIAA | 843,433 | 0 | 0 | 0 | For |
| Aberdeen | 721,531 | 0 | 0 | 0 | For |
| First Trust | 664,902 | 0 | 0 | 0 | For |
| Capitol Series Trust | 547,000 | 0 | 0 | 0 | For |
| TOUCHSTONE STRATEGIC TRUST | 517,507 | 0 | 0 | 0 | For |
| Dimensional | 488,764 | 0 | 0 | 0 | For |
| JPMorgan | 464,998 | 0 | 0 | 0 | For |
| American Century | 447,463 | 0 | 0 | 0 | For |
| Equitable | 381,070 | 0 | 0 | 0 | For |
| Jackson National | 359,423 | 0 | 0 | 0 | For |
| NEW ECONOMY FUND | 289,881 | 0 | 0 | 0 | For |
| Empower | 246,899 | 0 | 0 | 0 | For |
| AQR | 236,403 | 0 | 0 | 0 | For |
| Goldman Sachs | 218,905 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 213,459 | 0 | 0 | 0 | For |
| John Hancock | 191,443 | 0 | 0 | 0 | For |
Showing the 25 largest of 132 asset managers. All 132 are in the interactive database (link above).
Combines 5 wordings of this item as funds reported it.
97% Majority: yes · of votes cast
Description as filed by funds: Election of Directors: Elizabeth M. Anderson
BIOMARIN PHARMACEUTICAL INC.’s own tally for this item (“Elect Director: Elizabeth M. Anderson”): 160,575,395 for, 5,338,859 against, per its Form 8-K filed May 22, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “Proposal 1: Election of Directors Based on the votes set forth above, BioMarin's stockholders elected each of the ten nominees set forth above to serve as a director of BioMarin until the next annual meeting of stockholders and until his or her successor is duly elected and qualified, or, if sooner…”
Support: 97% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 132 asset managers below reported 88,397,404 for, 642,101 against, 66,717 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 32,152,236 | 1 | 0 | 0 | For |
| BlackRock | 12,596,604 | 0 | 0 | 0 | For |
| Dodge & Cox | 11,525,325 | 0 | 0 | 0 | For |
| Capital Group | 8,669,069 | 0 | 0 | 0 | For |
| Fidelity | 3,339,881 | 0 | 0 | 0 | For |
| State Street | 3,100,000 | 0 | 0 | 0 | For |
| PRIMECAP Odyssey Funds | 2,994,376 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 2,813,621 | 0 | 0 | 0 | For |
| Charles Schwab | 1,505,451 | 0 | 0 | 0 | For |
| TIAA | 843,433 | 0 | 0 | 0 | For |
| Aberdeen | 721,531 | 0 | 0 | 0 | For |
| First Trust | 664,902 | 0 | 0 | 0 | For |
| Capitol Series Trust | 547,000 | 0 | 0 | 0 | For |
| TOUCHSTONE STRATEGIC TRUST | 517,507 | 0 | 0 | 0 | For |
| Dimensional | 0 | 488,764 | 0 | 0 | Against |
| JPMorgan | 464,998 | 0 | 0 | 0 | For |
| American Century | 447,463 | 0 | 0 | 0 | For |
| Equitable | 381,070 | 0 | 0 | 0 | For |
| Jackson National | 353,795 | 5,628 | 0 | 0 | For |
| NEW ECONOMY FUND | 289,881 | 0 | 0 | 0 | For |
| Empower | 246,899 | 0 | 0 | 0 | For |
| AQR | 236,403 | 0 | 0 | 0 | For |
| Goldman Sachs | 218,905 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 213,459 | 0 | 0 | 0 | For |
| John Hancock | 110,269 | 81,174 | 0 | 0 | Mixed |
Showing the 25 largest of 132 asset managers. All 132 are in the interactive database (link above).
Combines 4 wordings of this item as funds reported it.
99.1% Majority: yes · of votes cast
Description as filed by funds: Election of Directors: Mark J. Enyedy
BIOMARIN PHARMACEUTICAL INC.’s own tally for this item (“Elect Director: Mark J. Enyedy”): 164,211,417 for, 1,412,156 against, per its Form 8-K filed May 22, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “Proposal 1: Election of Directors Based on the votes set forth above, BioMarin's stockholders elected each of the ten nominees set forth above to serve as a director of BioMarin until the next annual meeting of stockholders and until his or her successor is duly elected and qualified, or, if sooner…”
Support: 99.1% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 132 asset managers below reported 89,004,257 for, 35,248 against, 66,717 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 32,152,237 | 0 | 0 | 0 | For |
| BlackRock | 12,596,604 | 0 | 0 | 0 | For |
| Dodge & Cox | 11,525,325 | 0 | 0 | 0 | For |
| Capital Group | 8,669,069 | 0 | 0 | 0 | For |
| Fidelity | 3,339,881 | 0 | 0 | 0 | For |
| State Street | 3,100,000 | 0 | 0 | 0 | For |
| PRIMECAP Odyssey Funds | 2,994,376 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 2,813,621 | 0 | 0 | 0 | For |
| Charles Schwab | 1,505,451 | 0 | 0 | 0 | For |
| TIAA | 843,433 | 0 | 0 | 0 | For |
| Aberdeen | 721,531 | 0 | 0 | 0 | For |
| First Trust | 664,902 | 0 | 0 | 0 | For |
| Capitol Series Trust | 547,000 | 0 | 0 | 0 | For |
| TOUCHSTONE STRATEGIC TRUST | 517,507 | 0 | 0 | 0 | For |
| Dimensional | 488,764 | 0 | 0 | 0 | For |
| JPMorgan | 464,998 | 0 | 0 | 0 | For |
| American Century | 447,463 | 0 | 0 | 0 | For |
| Equitable | 381,070 | 0 | 0 | 0 | For |
| Jackson National | 359,423 | 0 | 0 | 0 | For |
| NEW ECONOMY FUND | 289,881 | 0 | 0 | 0 | For |
| Empower | 246,899 | 0 | 0 | 0 | For |
| AQR | 236,403 | 0 | 0 | 0 | For |
| Goldman Sachs | 218,905 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 213,459 | 0 | 0 | 0 | For |
| John Hancock | 191,443 | 0 | 0 | 0 | For |
Showing the 25 largest of 132 asset managers. All 132 are in the interactive database (link above).
Combines 4 wordings of this item as funds reported it.
99% Majority: yes · of votes cast
Description as filed by funds: Election of Directors: Maykin Ho
BIOMARIN PHARMACEUTICAL INC.’s own tally for this item (“Elect Director: Maykin Ho”): 164,039,826 for, 1,878,694 against, per its Form 8-K filed May 22, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “Proposal 1: Election of Directors Based on the votes set forth above, BioMarin's stockholders elected each of the ten nominees set forth above to serve as a director of BioMarin until the next annual meeting of stockholders and until his or her successor is duly elected and qualified, or, if sooner…”
Support: 99% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 132 asset managers below reported 89,014,900 for, 24,605 against, 66,717 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 32,152,237 | 0 | 0 | 0 | For |
| BlackRock | 12,596,604 | 0 | 0 | 0 | For |
| Dodge & Cox | 11,525,325 | 0 | 0 | 0 | For |
| Capital Group | 8,669,069 | 0 | 0 | 0 | For |
| Fidelity | 3,339,881 | 0 | 0 | 0 | For |
| State Street | 3,100,000 | 0 | 0 | 0 | For |
| PRIMECAP Odyssey Funds | 2,994,376 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 2,813,621 | 0 | 0 | 0 | For |
| Charles Schwab | 1,505,451 | 0 | 0 | 0 | For |
| TIAA | 843,433 | 0 | 0 | 0 | For |
| Aberdeen | 721,531 | 0 | 0 | 0 | For |
| First Trust | 664,902 | 0 | 0 | 0 | For |
| Capitol Series Trust | 547,000 | 0 | 0 | 0 | For |
| TOUCHSTONE STRATEGIC TRUST | 517,507 | 0 | 0 | 0 | For |
| Dimensional | 488,764 | 0 | 0 | 0 | For |
| JPMorgan | 464,998 | 0 | 0 | 0 | For |
| American Century | 447,463 | 0 | 0 | 0 | For |
| Equitable | 381,070 | 0 | 0 | 0 | For |
| Jackson National | 359,423 | 0 | 0 | 0 | For |
| NEW ECONOMY FUND | 289,881 | 0 | 0 | 0 | For |
| Empower | 246,899 | 0 | 0 | 0 | For |
| AQR | 236,403 | 0 | 0 | 0 | For |
| Goldman Sachs | 218,905 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 213,459 | 0 | 0 | 0 | For |
| John Hancock | 191,443 | 0 | 0 | 0 | For |
Showing the 25 largest of 132 asset managers. All 132 are in the interactive database (link above).
Combines 4 wordings of this item as funds reported it.
97% Majority: yes · of votes cast
Description as filed by funds: Election of Directors: Richard A. Meier
BIOMARIN PHARMACEUTICAL INC.’s own tally for this item (“Elect Director: Richard A. Meier”): 160,566,321 for, 5,338,585 against, per its Form 8-K filed May 22, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “Proposal 1: Election of Directors Based on the votes set forth above, BioMarin's stockholders elected each of the ten nominees set forth above to serve as a director of BioMarin until the next annual meeting of stockholders and until his or her successor is duly elected and qualified, or, if sooner…”
Support: 97% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 132 asset managers below reported 88,022,802 for, 1,016,703 against, 66,717 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 32,150,431 | 1,806 | 0 | 0 | For |
| BlackRock | 12,596,604 | 0 | 0 | 0 | For |
| Dodge & Cox | 11,525,325 | 0 | 0 | 0 | For |
| Capital Group | 8,669,069 | 0 | 0 | 0 | For |
| Fidelity | 3,339,881 | 0 | 0 | 0 | For |
| State Street | 3,099,903 | 97 | 0 | 0 | For |
| PRIMECAP Odyssey Funds | 2,994,376 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 2,813,621 | 0 | 0 | 0 | For |
| Charles Schwab | 1,505,451 | 0 | 0 | 0 | For |
| TIAA | 0 | 843,433 | 0 | 0 | Against |
| Aberdeen | 721,531 | 0 | 0 | 0 | For |
| First Trust | 664,902 | 0 | 0 | 0 | For |
| Capitol Series Trust | 547,000 | 0 | 0 | 0 | For |
| TOUCHSTONE STRATEGIC TRUST | 517,507 | 0 | 0 | 0 | For |
| Dimensional | 488,764 | 0 | 0 | 0 | For |
| JPMorgan | 464,998 | 0 | 0 | 0 | For |
| American Century | 447,463 | 0 | 0 | 0 | For |
| Equitable | 381,070 | 0 | 0 | 0 | For |
| Jackson National | 359,423 | 0 | 0 | 0 | For |
| NEW ECONOMY FUND | 289,881 | 0 | 0 | 0 | For |
| Empower | 246,899 | 0 | 0 | 0 | For |
| AQR | 236,403 | 0 | 0 | 0 | For |
| Goldman Sachs | 218,905 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 213,459 | 0 | 0 | 0 | For |
| John Hancock | 191,443 | 0 | 0 | 0 | For |
Showing the 25 largest of 132 asset managers. All 132 are in the interactive database (link above).
Combines 4 wordings of this item as funds reported it.
98% Majority: yes · of votes cast
Description as filed by funds: Election of Directors: Robert J. Hombach
BIOMARIN PHARMACEUTICAL INC.’s own tally for this item (“Elect Director: Robert J. Hombach”): 163,224,408 for, 2,694,927 against, per its Form 8-K filed May 22, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “Proposal 1: Election of Directors Based on the votes set forth above, BioMarin's stockholders elected each of the ten nominees set forth above to serve as a director of BioMarin until the next annual meeting of stockholders and until his or her successor is duly elected and qualified, or, if sooner…”
Support: 98% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 132 asset managers below reported 88,995,797 for, 43,708 against, 66,717 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 32,152,237 | 0 | 0 | 0 | For |
| BlackRock | 12,596,604 | 0 | 0 | 0 | For |
| Dodge & Cox | 11,525,325 | 0 | 0 | 0 | For |
| Capital Group | 8,669,069 | 0 | 0 | 0 | For |
| Fidelity | 3,339,881 | 0 | 0 | 0 | For |
| State Street | 3,100,000 | 0 | 0 | 0 | For |
| PRIMECAP Odyssey Funds | 2,994,376 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 2,813,621 | 0 | 0 | 0 | For |
| Charles Schwab | 1,505,451 | 0 | 0 | 0 | For |
| TIAA | 843,433 | 0 | 0 | 0 | For |
| Aberdeen | 721,531 | 0 | 0 | 0 | For |
| First Trust | 664,902 | 0 | 0 | 0 | For |
| Capitol Series Trust | 547,000 | 0 | 0 | 0 | For |
| TOUCHSTONE STRATEGIC TRUST | 517,507 | 0 | 0 | 0 | For |
| Dimensional | 488,764 | 0 | 0 | 0 | For |
| JPMorgan | 464,998 | 0 | 0 | 0 | For |
| American Century | 447,463 | 0 | 0 | 0 | For |
| Equitable | 381,070 | 0 | 0 | 0 | For |
| Jackson National | 359,423 | 0 | 0 | 0 | For |
| NEW ECONOMY FUND | 289,881 | 0 | 0 | 0 | For |
| Empower | 246,899 | 0 | 0 | 0 | For |
| AQR | 236,403 | 0 | 0 | 0 | For |
| Goldman Sachs | 218,905 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 213,459 | 0 | 0 | 0 | For |
| John Hancock | 191,443 | 0 | 0 | 0 | For |
Showing the 25 largest of 132 asset managers. All 132 are in the interactive database (link above).
Combines 4 wordings of this item as funds reported it.
99.6% Majority: yes · of votes cast
Description as filed by funds: Election of Directors: Timothy P. Walbert
BIOMARIN PHARMACEUTICAL INC.’s own tally for this item (“Elect Director: Timothy P. Walbert”): 165,166,799 for, 662,209 against, per its Form 8-K filed May 22, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “Proposal 1: Election of Directors Based on the votes set forth above, BioMarin's stockholders elected each of the ten nominees set forth above to serve as a director of BioMarin until the next annual meeting of stockholders and until his or her successor is duly elected and qualified, or, if sooner…”
Support: 99.6% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 132 asset managers below reported 89,029,307 for, 10,198 against, 66,717 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 32,152,237 | 0 | 0 | 0 | For |
| BlackRock | 12,596,604 | 0 | 0 | 0 | For |
| Dodge & Cox | 11,525,325 | 0 | 0 | 0 | For |
| Capital Group | 8,669,069 | 0 | 0 | 0 | For |
| Fidelity | 3,339,881 | 0 | 0 | 0 | For |
| State Street | 3,100,000 | 0 | 0 | 0 | For |
| PRIMECAP Odyssey Funds | 2,994,376 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 2,813,621 | 0 | 0 | 0 | For |
| Charles Schwab | 1,505,451 | 0 | 0 | 0 | For |
| TIAA | 843,433 | 0 | 0 | 0 | For |
| Aberdeen | 721,531 | 0 | 0 | 0 | For |
| First Trust | 664,902 | 0 | 0 | 0 | For |
| Capitol Series Trust | 547,000 | 0 | 0 | 0 | For |
| TOUCHSTONE STRATEGIC TRUST | 517,507 | 0 | 0 | 0 | For |
| Dimensional | 488,764 | 0 | 0 | 0 | For |
| JPMorgan | 464,998 | 0 | 0 | 0 | For |
| American Century | 447,463 | 0 | 0 | 0 | For |
| Equitable | 381,070 | 0 | 0 | 0 | For |
| Jackson National | 359,423 | 0 | 0 | 0 | For |
| NEW ECONOMY FUND | 289,881 | 0 | 0 | 0 | For |
| Empower | 246,899 | 0 | 0 | 0 | For |
| AQR | 236,403 | 0 | 0 | 0 | For |
| Goldman Sachs | 218,905 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 213,459 | 0 | 0 | 0 | For |
| John Hancock | 191,443 | 0 | 0 | 0 | For |
Showing the 25 largest of 132 asset managers. All 132 are in the interactive database (link above).
Combines 4 wordings of this item as funds reported it.
98% Majority: yes · of votes cast
Description as filed by funds: Election of Directors: Willard Dere
BIOMARIN PHARMACEUTICAL INC.’s own tally for this item (“Elect Director: Willard Dere”): 163,380,097 for, 2,536,182 against, per its Form 8-K filed May 22, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “Proposal 1: Election of Directors Based on the votes set forth above, BioMarin's stockholders elected each of the ten nominees set forth above to serve as a director of BioMarin until the next annual meeting of stockholders and until his or her successor is duly elected and qualified, or, if sooner…”
Support: 98% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 132 asset managers below reported 88,995,797 for, 43,708 against, 66,717 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 32,152,237 | 0 | 0 | 0 | For |
| BlackRock | 12,596,604 | 0 | 0 | 0 | For |
| Dodge & Cox | 11,525,325 | 0 | 0 | 0 | For |
| Capital Group | 8,669,069 | 0 | 0 | 0 | For |
| Fidelity | 3,339,881 | 0 | 0 | 0 | For |
| State Street | 3,100,000 | 0 | 0 | 0 | For |
| PRIMECAP Odyssey Funds | 2,994,376 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 2,813,621 | 0 | 0 | 0 | For |
| Charles Schwab | 1,505,451 | 0 | 0 | 0 | For |
| TIAA | 843,433 | 0 | 0 | 0 | For |
| Aberdeen | 721,531 | 0 | 0 | 0 | For |
| First Trust | 664,902 | 0 | 0 | 0 | For |
| Capitol Series Trust | 547,000 | 0 | 0 | 0 | For |
| TOUCHSTONE STRATEGIC TRUST | 517,507 | 0 | 0 | 0 | For |
| Dimensional | 488,764 | 0 | 0 | 0 | For |
| JPMorgan | 464,998 | 0 | 0 | 0 | For |
| American Century | 447,463 | 0 | 0 | 0 | For |
| Equitable | 381,070 | 0 | 0 | 0 | For |
| Jackson National | 359,423 | 0 | 0 | 0 | For |
| NEW ECONOMY FUND | 289,881 | 0 | 0 | 0 | For |
| Empower | 246,899 | 0 | 0 | 0 | For |
| AQR | 236,403 | 0 | 0 | 0 | For |
| Goldman Sachs | 218,905 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 213,459 | 0 | 0 | 0 | For |
| John Hancock | 191,443 | 0 | 0 | 0 | For |
Showing the 25 largest of 132 asset managers. All 132 are in the interactive database (link above).
Combines 6 wordings of this item as funds reported it.
95% Approved · of votes cast
Description as filed by funds: To approve an amendment to the Company's 2017 Equity Incentive Plan, as amended.
BIOMARIN PHARMACEUTICAL INC.’s own tally for this item (“4. Approval of an Amendment to the 2017 Equity Incentive Plan The approval of the Plan Amendment received the following votes”): 157,280,864 for, 7,747,768 against — passed, per its Form 8-K filed May 22, 2025 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “Based on the votes set forth above, BioMarin's stockholders approved the Plan Amendment.”
Support: 95% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Also reported under other wordings, matched to the same row of BIOMARIN PHARMACEUTICAL INC.’s official tally and shown with their own fund figures; their managers are not in the figures or the table on this card: “Amend Omnibus Stock Plan” (5 managers, Fund and manager reports combined; may count the same shares twice; no share total shown).
The 139 asset managers below reported 88,045,342 for, 728,548 against, 66,717 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 32,152,236 | 1 | 0 | 0 | For |
| BlackRock | 12,596,604 | 0 | 0 | 0 | For |
| Dodge & Cox | 11,525,325 | 0 | 0 | 0 | For |
| Capital Group | 8,669,069 | 0 | 0 | 0 | For |
| Fidelity | 3,339,881 | 0 | 0 | 0 | For |
| State Street | 3,099,903 | 97 | 0 | 0 | For |
| PRIMECAP Odyssey Funds | 2,994,376 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 2,813,621 | 0 | 0 | 0 | For |
| Charles Schwab | 1,505,451 | 0 | 0 | 0 | For |
| TIAA | 843,433 | 0 | 0 | 0 | For |
| Aberdeen | 721,531 | 0 | 0 | 0 | For |
| First Trust | 664,902 | 0 | 0 | 0 | For |
| Capitol Series Trust | 547,000 | 0 | 0 | 0 | For |
| TOUCHSTONE STRATEGIC TRUST | 517,507 | 0 | 0 | 0 | For |
| Dimensional | 488,764 | 0 | 0 | 0 | For |
| JPMorgan | 464,998 | 0 | 0 | 0 | For |
| American Century | 0 | 447,463 | 0 | 0 | Against |
| Equitable | 381,070 | 0 | 0 | 0 | For |
| Jackson National | 359,423 | 0 | 0 | 0 | For |
| NEW ECONOMY FUND | 289,881 | 0 | 0 | 0 | For |
| AQR | 236,403 | 0 | 0 | 0 | For |
| Goldman Sachs | 218,905 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 213,459 | 0 | 0 | 0 | For |
| John Hancock | 191,443 | 0 | 0 | 0 | For |
| Nationwide | 162,879 | 0 | 0 | 0 | For |
Showing the 25 largest of 139 asset managers. All 139 are in the interactive database (link above).
Combines 13 wordings of this item as funds reported it.
94% Approved · of votes cast
Prior year: 93.0% for (May 21, 2024 meeting) ▲ 0.9 pts
Description as filed by funds: To approve, on an advisory basis, the compensation of the Company's Named Executive Officers as disclosed in the Proxy Statement.
BIOMARIN PHARMACEUTICAL INC.’s own tally for this item (“3. Advisory Vote on the Compensation of Named Executive Officers The advisory (non-binding) vote to approve the compensation of BioMarin's named executive officers, as set forth in the Proxy Statement, received the follo”): 155,351,652 for, 10,227,321 against — passed, per its Form 8-K filed May 22, 2025 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “Based on the votes set forth above, BioMarin's stockholders approved, on an advisory basis, the compensation of BioMarin's named executive officers, as set forth in the Proxy Statement.”
Support: 94% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 32,149,793 | 2,444 | 0 | 0 | For |
| BlackRock | 12,596,604 | 0 | 0 | 0 | For |
| Dodge & Cox | 11,525,325 | 0 | 0 | 0 | For |
| Capital Group | 8,669,069 | 0 | 0 | 0 | For |
| Fidelity | 3,339,881 | 0 | 0 | 0 | For |
| State Street | 3,097,689 | 2,311 | 0 | 0 | For |
| PRIMECAP Odyssey Funds | 2,994,376 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 2,813,621 | 0 | 0 | 0 | For |
| Charles Schwab | 1,505,451 | 0 | 0 | 0 | For |
| TIAA | 0 | 843,433 | 0 | 0 | Against |
| Aberdeen | 721,531 | 0 | 0 | 0 | For |
| First Trust | 664,902 | 0 | 0 | 0 | For |
| Capitol Series Trust | 547,000 | 0 | 0 | 0 | For |
| TOUCHSTONE STRATEGIC TRUST | 517,507 | 0 | 0 | 0 | For |
| Dimensional | 488,764 | 0 | 0 | 0 | For |
| JPMorgan | 464,998 | 0 | 0 | 0 | For |
| American Century | 447,463 | 0 | 0 | 0 | For |
| Equitable | 381,070 | 0 | 0 | 0 | For |
| Jackson National | 359,423 | 0 | 0 | 0 | For |
| NEW ECONOMY FUND | 289,881 | 0 | 0 | 0 | For |
| Empower | 246,899 | 0 | 0 | 0 | For |
| AQR | 236,403 | 0 | 0 | 0 | For |
| Goldman Sachs | 218,905 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 213,459 | 0 | 0 | 0 | For |
| John Hancock | 191,443 | 0 | 0 | 0 | For |
Fund voting reports, all 129 managers: 87,889,268 for, 1,107,142 against, 66,717 abstained. Showing the 25 largest; every one is in the interactive database (link above).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| PRIMECAP MANAGEMENT CO/CA/ | 17,067,608 | 0 | 0 | 0 | For |
| Dodge & Cox | 14,172,833 | 0 | 0 | 0 | For |
| VIKING GLOBAL INVESTORS LP | 10,588,163 | 0 | 0 | 0 | For |
| Capital Research Global Investors | 9,147,555 | 0 | 0 | 0 | For |
| BlackRock | 8,919,928 | 16,657 | 0 | 0 | For |
| State Street | 7,749,968 | 74,178 | 0 | 0 | For |
| GEODE CAPITAL MANAGEMENT, LLC | 3,364,050 | 0 | 0 | 0 | For |
| Charles Schwab | 1,620,334 | 0 | 0 | 0 | For |
| Northern Trust | 1,371,304 | 16,832 | 0 | 0 | For |
| AQR | 1,328,233 | 0 | 0 | 0 | For |
| MELLON INVESTMENTS Corp | 1,239,265 | 0 | 0 | 0 | For |
| Palo Alto Investors LP | 1,136,224 | 0 | 0 | 0 | For |
| JPMorgan | 1,093,699 | 0 | 0 | 0 | For |
| Soleus Capital Management, L.P. | 1,089,304 | 0 | 0 | 0 | For |
| AMERIPRISE FINANCIAL INC | 1,062,067 | 0 | 0 | 0 | For |
| DnB Asset Management AS | 1,001,675 | 0 | 0 | 0 | For |
| Nuveen | 0 | 953,511 | 0 | 0 | Against |
| Goldman Sachs | 801,797 | 0 | 0 | 0 | For |
| FULLER & THALER ASSET MANAGEMENT, INC. | 798,699 | 0 | 0 | 0 | For |
| Vanguard | 759,441 | 0 | 0 | 0 | For |
| Aberdeen | 751,147 | 0 | 0 | 0 | For |
| FORT WASHINGTON INVESTMENT ADVISORS INC /OH/ | 647,217 | 0 | 0 | 0 | For |
| CALIFORNIA PUBLIC EMPLOYEES RETIREMENT SYSTEM | 0 | 623,928 | 0 | 0 | Against |
| Citadel | 616,550 | 0 | 0 | 0 | For |
| Candriam S.C.A. | 0 | 607,862 | 0 | 0 | Against |
Institutional-manager reports, all 462 managers: 103,871,557 for, 7,626,985 against, 453,532 abstained, 4,165 not voted. Showing the 25 largest; every one is in the interactive database (link above).
Combines 3 wordings of this item as funds reported it.
96% Approved · of votes cast
Prior year: 96.1% for (May 21, 2024 meeting) ▼ 0.3 pts
Description as filed by funds: To ratify the selection of KPMG LLP as the independent registered public accounting firm for the Company for the fiscal year ending December 31, 2025.
BIOMARIN PHARMACEUTICAL INC.’s own tally for this item (“2. Ratification of the Selection of Independent Registered Public Accounting Firm The ratification of the selection of KPMG LLP as BioMarin's independent registered public accounting firm for the fiscal year ending Decem”): 168,601,089 for, 7,442,009 against — passed, per its Form 8-K filed May 22, 2025 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “Based on the votes set forth above, BioMarin's stockholders ratified the selection of KPMG LLP as BioMarin's independent registered public accounting firm to serve for the year ending December 31, 2025.”
Support: 96% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Also reported under other wordings, matched to the same row of BIOMARIN PHARMACEUTICAL INC.’s official tally and shown with their own fund figures; their managers are not in the figures or the table on this card: “Ratify Appointment of Independent Auditors” (2 managers, 1,350 for, 30,169 against).
The 131 asset managers below reported 88,973,828 for, 35,508 against, 66,717 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 32,150,430 | 1,807 | 0 | 0 | For |
| BlackRock | 12,596,604 | 0 | 0 | 0 | For |
| Dodge & Cox | 11,525,325 | 0 | 0 | 0 | For |
| Capital Group | 8,669,069 | 0 | 0 | 0 | For |
| Fidelity | 3,339,881 | 0 | 0 | 0 | For |
| State Street | 3,099,809 | 191 | 0 | 0 | For |
| PRIMECAP Odyssey Funds | 2,994,376 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 2,813,621 | 0 | 0 | 0 | For |
| Charles Schwab | 1,505,451 | 0 | 0 | 0 | For |
| TIAA | 843,433 | 0 | 0 | 0 | For |
| Aberdeen | 721,531 | 0 | 0 | 0 | For |
| First Trust | 664,902 | 0 | 0 | 0 | For |
| Capitol Series Trust | 547,000 | 0 | 0 | 0 | For |
| TOUCHSTONE STRATEGIC TRUST | 517,507 | 0 | 0 | 0 | For |
| Dimensional | 488,764 | 0 | 0 | 0 | For |
| JPMorgan | 464,998 | 0 | 0 | 0 | For |
| American Century | 447,463 | 0 | 0 | 0 | For |
| Equitable | 381,070 | 0 | 0 | 0 | For |
| Jackson National | 359,423 | 0 | 0 | 0 | For |
| NEW ECONOMY FUND | 289,881 | 0 | 0 | 0 | For |
| Empower | 246,899 | 0 | 0 | 0 | For |
| AQR | 236,403 | 0 | 0 | 0 | For |
| Goldman Sachs | 218,905 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 213,459 | 0 | 0 | 0 | For |
| John Hancock | 191,443 | 0 | 0 | 0 | For |
Showing the 25 largest of 131 asset managers. All 131 are in the interactive database (link above).
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 191,755,802 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Vanguard | 16.77% |
| 2 | BlackRock | 6.57% |
| 3 | Dodge & Cox | 6.01% |
| 4 | Capital Group | 4.52% |
| 5 | Fidelity | 1.74% |
| 6 | State Street | 1.62% |
| 7 | PRIMECAP Odyssey Funds | 1.56% |
| 8 | Columbia Threadneedle | 1.47% |
| 9 | Charles Schwab | 0.79% |
| 10 | TIAA | 0.44% |
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | PRIMECAP MANAGEMENT CO/CA/ | 8.90% |
| 2 | Dodge & Cox | 7.39% |
| 3 | VIKING GLOBAL INVESTORS LP | 5.52% |
| 4 | Capital Research Global Investors | 4.77% |
| 5 | BlackRock | 4.66% |
| 6 | State Street | 4.08% |
| 7 | GEODE CAPITAL MANAGEMENT, LLC | 1.75% |
| 8 | Charles Schwab | 0.85% |
| 9 | Northern Trust | 0.72% |
| 10 | AQR | 0.69% |
As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.
| Holder | Shares | % outstanding | Source, as of |
|---|---|---|---|
| The Vanguard Group | 18,992,533 | 9.90% | Proxy statement (DEF 14A), proxy filed April 8, 2025 |
| BlackRock, Inc. | 17,560,751 | 9.16% | Schedule 13G, filed January 21, 2026 |
| PRIMECAP MANAGEMENT CO/CA/ | 15,795,383 | 8.24% | Schedule 13G, filed August 14, 2025 |
| Dodge & Cox | 13,994,063 | 7.30% | Proxy statement (DEF 14A), proxy filed April 8, 2025 |
| Vanguard Capital Management | 10,113,219 | 5.27% | Schedule 13G, filed April 29, 2026 |
| Entities affiliated with Viking Global Investors LP | 9,753,293 | 5.09% | Proxy statement (DEF 14A), proxy filed April 8, 2025 |
| Capital Research Global Investors | 9,150,655 | 4.77% | Schedule 13G, filed May 13, 2025 |
| State Street | 8,463,090 | 4.41% | Form 13F, quarter ended March 31, 2025 |
| VIKING GLOBAL INVESTORS LP | 8,322,179 | 4.34% | Schedule 13G, filed November 14, 2025 |
| Norges Bank | 3,478,512 | 1.81% | Form 13F, quarter ended March 31, 2025 |
Percentages above are of 191,755,802 shares outstanding, as reported by BIOMARIN PHARMACEUTICAL INC. on its Form 10-Q dated March 31, 2025 (see the filing on EDGAR). This is the count contemporaneous with the 2024-2025 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.
At BIOMARIN PHARMACEUTICAL INC.'s shareholder meeting held May 20, 2025, in the 2024-2025 proxy season, 554 asset managers reported votes on at least one of its 13 ballot items in their SEC Form N-PX filings, covering 7,346 separate fund positions. On the most widely held item on that ballot — To approve, on an advisory basis, the compensation of the Company's Named Executive Officers as… — BIOMARIN PHARMACEUTICAL INC.'s filing reports the proposal as approved, with 94% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: BIOMARIN PHARMACEUTICAL INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on May 22, 2025.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from BIOMARIN PHARMACEUTICAL INC.’s 10-Q dated March 31, 2025. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.
BIOMARIN PHARMACEUTICAL INC. proxy season coverage: 2023-2024 · 2024-2025 (this page) · 2025-2026.
Proxy Votes Now, “BIOMARIN PHARMACEUTICAL (BMRN) 2025 Annual Meeting: Vote Results”, https://proxyvotesnow.com/company/biomarin-pharmaceutical-inc/2025 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.